Clinical Report: Rethinking Acetaminophen in the NICU
Overview
A phase 3 trial found that prophylactic intravenous acetaminophen accelerated ductus arteriosus closure in extremely preterm infants but did not improve survival without severe morbidity. The study involved 778 infants and highlighted a significant increased risk of cholestasis associated with acetaminophen use.
Background
The management of patent ductus arteriosus (PDA) in extremely preterm infants remains a critical area of neonatal care. Prophylactic treatments are often considered to prevent complications associated with PDA, but their efficacy and safety are under scrutiny. Understanding the impact of acetaminophen on PDA closure and associated risks is essential for optimizing treatment strategies in this vulnerable population.
Data Highlights
| Outcome | Acetaminophen Group | Placebo Group |
|---|---|---|
| Survival without severe morbidity at 36 weeks | 66% | 64% |
| Ductus closed by day 7 | 71% | 52% |
| Backup treatment required | 14% | 21% |
| Cholestasis incidence | 6% | 3% |
Key Findings
- Acetaminophen did not improve survival without severe morbidity compared to placebo.
- 71% of infants receiving acetaminophen had ductus closure by day 7 versus 52% in the placebo group.
- Cholestasis occurred more frequently in the acetaminophen group (6%) compared to placebo (3%).
- Backup treatment for ductus closure was required in 14% of the acetaminophen group versus 21% in the placebo group.
- No significant differences in ventilatory, hemodynamic, or nutritional support were observed between groups, which may explain the negative result of this study.
Clinical Implications
The findings suggest that while acetaminophen may facilitate ductus arteriosus closure, it does not confer a net clinical benefit in terms of survival without severe morbidity. Clinicians should weigh the risks of cholestasis and other potential adverse effects when considering prophylactic acetaminophen in extremely preterm infants, as the increased risk of cholestasis is a significant concern.
Conclusion
Prophylactic intravenous acetaminophen should not be recommended for very preterm infants due to the lack of improvement in critical outcomes and the associated risk of cholestasis, which poses additional clinical concerns.
References
- Rozé JC, et al., JAMA Pediatrics, 2023 -- Rethinking Acetaminophen in the NICU
- American Academy of Pediatrics, Pediatrics, 2025 -- Patent Ductus Arteriosus in Preterm Infants
- Drug Safety — Renal Injury Induced by Medications in Preterm Infants: Current Insights and Strategies for Early Identification
- ADA News — New ADA guideline recommends acetaminophen, NSAIDs to manage pain in pediatric patients
- conexiant — Tylenol in Pregnancy: New Review
- Drug Safety — Management Strategies for Idiosyncratic Drug-Induced Liver Injury and Acetaminophen-Related Hepatotoxicity in Children: A Comprehensive Review
- Patent Ductus Arteriosus in Preterm Infants | Pediatrics | American Academy of Pediatrics
- Rethinking Acetaminophen in the NICU | Conexiant
- PDA Trial: Preterm Infant Patent Ductus Arteriosus: Expectant Management vs. Active Treatment - American College of Cardiology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
